A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients
| Autor: | N. Premasathian, Soontorn Pinpaiboon, Nuttasith Larpparisuth, Ratchawat Promraj, Nartsiri Ratchawang, A. Vongwiwatana, Peenida Skulratanasak |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Urology Mycophenolate Tacrolimus Mycophenolic acid Pharmacokinetics Statistical significance Drugs Generic Humans Medicine Postoperative Period Prospective Studies Prospective cohort study Kidney transplantation Transplantation business.industry Area under the curve Middle Aged Mycophenolic Acid Thailand medicine.disease Kidney Transplantation Treatment Outcome Area Under Curve Pharmacodynamics Drug Therapy Combination Female Steroids Surgery business Immunosuppressive Agents Follow-Up Studies medicine.drug |
| Zdroj: | Transplantation Proceedings. 51:2629-2632 |
| ISSN: | 0041-1345 |
| DOI: | 10.1016/j.transproceed.2019.03.063 |
| Popis: | Background Mycophenolic acid (MPA) is one of the main immunosuppressive regimens used after kidney transplantation (KT). The less expensive, generic form of mycophenolate mofetil (MMF) (Immucept®) is recently available in Thailand. Comparisons of the pharmacokinetic profiles between the original and generic forms of MMF among post-KT patients are limited. Methods This prospective cohort study recruited KT patients receiving stable doses of MMF 1000 mg daily along with tacrolimus and steroids. All participants were prescribed CellCept® 500 mg every 12 hours for at least 2 weeks before measuring the MPA area under the curve from 0 to 12 hours (AUC0-12). CellCept® was switched to Immucept® 500 mg every 12 hours for 2 weeks and MPA AUC0-12 was remeasured. Results Twenty patients with a median follow-up time of 35.4 (11.13–198.83) months were enrolled. Mean MPA AUC0-12 of Immucept® was higher than CellCept® without statistical significance (48.27 ± 2.31 μg⋅hr/mL vs 42.19 ± 15.20 μg⋅hr/mL; P value = .59). No difference was revealed regarding the minimum measured concentration, maximum measured concentration, and time point with maximum concentration between both drugs. While on CellCept®, 5 patients (25%) had an MPA AUC0-12 60.0 μg⋅hr./mL when treated with CellCept® and Immucept®, respectively. Conclusion Generic MMF exhibited a comparable pharmacodynamic profile as the original formulation. MPA AUC0-12 was more than 30.0 μg⋅hr/mL among most patients receiving MMF 1000 mg/day. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect